Stock Movers: Novartis, Soitec, Nordex (Podcast)

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Novartis shares fall as much as 3.9% after the Swiss pharma group’s potential blockbuster heart drug, pelacarsen, failed in a final-stage study. It’s the company’s second trial disappointment within a week, coming days after Novartis temporarily paused trials of an experimental cell therapy for autoimmune diseases.
- Nordex shares rise as much as 8.8%, the most in over four months, after being upgraded to buy at BofA Global Research. Analysts said they see “significant” earnings upgrades ahead following a period of underperformance from the wind turbine company.
- Soitec surges as much as 13%, the most since July 23, as the French chip material company lifted its revenue guidance for the second quarter of 2027, citing accelerating Photonics-SOI demand. The firm outlined expectations for full-year revenue in this segment to be 2.5x-3x the previous year’s level.

See omnystudio.com/listener for privacy information.